Neuropsychiatric aspects of long COVID: A comprehensive review

Takafumi Kubota, Naoto Kuroda, Daichi Sone, Takafumi Kubota, Naoto Kuroda, Daichi Sone

Abstract

Although some patients have persistent symptoms or develop new symptoms following coronavirus disease 2019 (COVID-19) infection, neuropsychiatric aspects of long COVID are not well known. This review summarizes and provides an update on the neuropsychiatric dimensions of long COVID. Its neuropsychiatric manifestations commonly include fatigue, cognitive impairment, sleep disorders, depression, anxiety, and post-traumatic stress disorder. There are no specific tests for long COVID, but some characteristic findings such as hypometabolism on positron emission tomography have been reported. The possible mechanisms of long COVID include inflammation, ischemic effects, direct viral invasion, and social and environmental changes. Some patient characteristics and the severity and complications of acute COVID-19 infection may be associated with an increased risk of neuropsychiatric symptoms. Long COVID may resolve spontaneously or persist, depending on the type of neuropsychiatric symptoms. Although established treatments are lacking, various psychological and pharmacological treatments have been attempted. Vaccination against COVID-19 infection plays a key role in the prevention of long coronavirus disease. With differences among the SARS-CoV-2 variants, including the omicron variant, the aspects of long COVID are likely to change in the future. Further studies clarifying the aspects of long COVID to develop effective treatments are warranted.

Keywords: COVID-19; long COVID; neurology; post COVID-19 condition; psychiatry.

© 2022 The Authors. Psychiatry and Clinical Neurosciences published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society of Psychiatry and Neurology.

References

    1. Guan W, Ni Z, Hu YHYYH et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020; 382: 1708–1720.
    1. WHO Coronavirus (COVID‐19) Dashboard | WHO Coronavirus (COVID‐19) Dashboard With Vaccination Data [Cited 12 June 2022.] Available from URL:
    1. Mao L, Jin H, Wang M et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020; 77: 683–690.
    1. A clinical case definition of post COVID‐19 condition by a Delphi consensus, 6 October 2021 [Cited 9 June 2022.] Available from URL:
    1. Long COVID or Post‐COVID Conditions | CDC [Cited 9 June 2022.] Available from URL:
    1. Nakamura ZM, Nash RP, Laughon SL, Rosenstein DL. Neuropsychiatric complications of COVID‐19. Curr. Psychiatry Rep. 2021; 23: 25.
    1. Lopez‐Leon S, Wegman‐Ostrosky T, Perelman C et al. More than 50 long‐term effects of COVID‐19: A systematic review and meta‐analysis. Sci. Rep. 2021; 11: 16144.
    1. Badenoch JB, Rengasamy ER, Watson C et al. Persistent neuropsychiatric symptoms after COVID‐19: A systematic review and meta‐analysis. Brain Commun. 2021; 4: fcab297.
    1. Overview | COVID‐19 rapid guideline: Managing the long‐term effects of COVID‐19 | Guidance | NICE [Cited 9 August 2022.] Available from URL:
    1. National Institute for Health and Care Excellence (NICE) SIGN (SIGN) and RC of GP (RCGP) . COVID‐19 rapid guideline: Managing the long‐term effects of COVID‐19. 2022.
    1. Venkatesan P. NICE guideline on long COVID. Lancet Respir. Med. 2021; 9: 129 [Cited 9 August 2022.] Available from URL: .
    1. Taquet M, Sillett R, Zhu L et al. Neurological and psychiatric risk trajectories after SARS‐CoV‐2 infection: An analysis of 2‐year retrospective cohort studies including 1 284 437 patients. Lancet Psychiatry 2022; 9: 815–827.
    1. Desgranges F, Tadini E, Munting A et al. Post‐COVID‐19 syndrome in outpatients: A cohort study. J. Gen. Intern. Med. 2022; 37: 1943–1952.
    1. Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID‐19 and psychiatric disorder: Retrospective cohort studies of 62 354 COVID‐19 cases in the USA. Lancet Psychiatry 2021; 8: 130–140.
    1. Stallmach A, Kesselmeier M, Bauer M, Gramlich J, Finke K. Comparison of fatigue, cognitive dysfunction and psychological disorders in post‐COVID patients and patients after sepsis: Is there a specific constellation? Infection 2022; 50: 661–669.
    1. Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS‐CoV‐2. Lancet 2022; 399: 2263–2264 [Cited 25 July 2022.] Available from URL: .
    1. A life altered by long COVID – Susan's experience [Cited 16 October 2022.] Available from URL:
    1. Huang C, Huang L, Wang Y et al. 6‐month consequences of COVID‐19 in patients discharged from hospital: A cohort study. Lancet 2021; 397: 220–232.
    1. Davis HE, Assaf GS, McCorkell L et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. eClinicalMedicine 2021; 38: 101019.
    1. Tabacof L, Tosto‐Mancuso J, Wood J et al. Post‐acute COVID‐19 syndrome negatively impacts physical function, cognitive function, health‐related quality of life, and participation. Am. J. Phys. Med. Rehabil. 2022; 101: 48–52.
    1. Frontera JA, Yang D, Medicherla C et al. Trajectories of neurologic recovery 12 months after hospitalization for COVID‐19: A prospective longitudinal study. Neurology 2022; 99: e33–e45.
    1. Lombardo MDM, Foppiani A, Peretti GM et al. Long‐term coronavirus disease 2019 complications in inpatients and outpatients: A one‐year follow‐up cohort study. Open Forum Infect. Dis. 2021; 8: 1–8.
    1. Can COVID‐19 Cause Insomnia? | Everyday Health [Cited 16 October 2022.] Available from URL:
    1. Fernández‐de‐las‐Peñas C, Gómez‐Mayordomo V, De‐la‐Llave‐Rincón AI et al. Anxiety, depression and poor sleep quality as long‐term post‐COVID sequelae in previously hospitalized patients: A multicenter study. J. Infect. 2021; 83: 504–506.
    1. Sleep P, Index Q. Sleep and circadian health of critical COVID‐19 survivors 3 months after hospital discharge. Crit. Care Med. 2022; 50: 945–954.
    1. Pataka A, Kotoulas S, Sakka E, Katsaounou P, Pappa S. Sleep dysfunction in COVID‐19 patients: Prevalence, risk factors, mechanisms, and management. J. Pers. Med. 2021; 11: 1203.
    1. Lee KK, Birring SS. Cough and sleep. Lung 2010; 188: 91–94.
    1. Ferri S, Tammaro S, Retucci M et al. Impact of cough on insomnia and sleep quality in bronchiectasis. Eur. Respir. J. 2020; 56: 2372 Available from URL: .
    1. Boiko DI, Skrypnikov AM, Shkodina AD, Hasan MM. Circadian rhythm disorder and anxiety as mental health complications in post‐COVID‐19. Environ. Sci. Pollut. Res. 2022; 29: 28062–28069.
    1. Crivelli L, Palmer K, Calandri I et al. Changes in cognitive functioning after COVID‐19: A systematic review and meta‐analysis. Alzheimers Dement. 2022; 18: 1047–1066.
    1. Long COVID: Brain fog | Long‐term effects of COVID‐19 [Cited 17 October 2022.] Available from URL:
    1. Pooya AAA, Akbari A, Kabiri M et al. Long COVID syndrome‐associated brain fog. 2021.
    1. Henneghan AM, Lewis KA, Gill E, Kesler SR. Cognitive impairment in non‐critical, mild‐to‐moderate COVID‐19 survivors. Front. Psychol. 2022; 13: 770459.
    1. Cecchetti G, Agosta F, Canu E et al. Cognitive, EEG, and MRI features of COVID‐19 survivors: A 10‐month study. J. Neurol. 2022; 269: 3400–3412.
    1. Miskowiak KW, Johnsen S, Sattler SM et al. Cognitive impairments four months after COVID‐19 hospital discharge: Pattern, severity and association with illness variables. Eur. Neuropsychopharmacol. 2021; 46: 39–48 Available from URL: .
    1. Woo MS, Malsy J, Pöttgen J et al. Frequent neurocognitive deficits after recovery from mild COVID‐19. Brain Commun. 2020; 2: 1–9.
    1. García‐Sánchez C, Calabria M, Grunden N et al. Neuropsychological deficits in patients with cognitive complaints after COVID‐19. Brain Behav. 2022; 12: 1–11.
    1. Lamontagne SJ, Winters MF, Pizzagalli DA, Olmstead MC. Post‐acute sequelae of COVID‐19: Evidence of mood & cognitive impairment. Brain Behav. Immun. Health 2021; 17: 100347.
    1. Del Brutto OH, Rumbea DA, Recalde BY, Mera RM. Cognitive sequelae of long COVID may not be permanent: A prospective study. Eur. J. Neurol. 2022; 29: 1218–1221.
    1. Zhao S, Shibata K, Hellyer PJ et al. Rapid vigilance and episodic memory decrements in COVID‐19 survivors. Brain Commun. 2022; 4: fcab29 [Cited 30 June 2022.] Available from URL: 10.1093/braincomms/fcab295.
    1. Renaud‐Charest O, Lui LMW, Eskander S et al. Onset and frequency of depression in post‐COVID‐19 syndrome: A systematic review. J. Psychiatr. Res. 2021; 144: 129 [Cited 6 July 2022.] Available from URL: .
    1. Houben‐Wilke S, Goërtz YMJ, Delbressine JM et al. The impact of long COVID‐19 on mental health: Observational 6‐month follow‐up study. JMIR Ment. Health 2022; 9: 1–13.
    1. Izquierdo MR, Jesús A, Ramos L et al. Long COVID 12 months after discharge: Persistent symptoms in patients hospitalised due to COVID‐19 and patients hospitalised due to other causes – A multicentre cohort study. BMC Med. 2022; 20: 1–10.
    1. Greene T, El‐leithy S, Billings J, Albert I, Birch J, Campbell M. Anticipating PTSD in severe COVID survivors: The case for screen‐and‐treat. Eur. J. Psychotraumatol. 2022; 13: 1–5.
    1. Naidu SB, Shah AJ, Saigal A et al. The high mental health burden of “Long COVID” and its association with on‐going physical and respiratory symptoms in all adults discharged from hospital. Eur. Respir. J. 2021; 57: 2004364 [Cited 17 July 2022.] Available from URL: .
    1. Damiano RF, Caruso MJG, Cincoto AV et al. Post‐COVID‐19 psychiatric and cognitive morbidity: Preliminary findings from a Brazilian cohort study. Gen. Hosp. Psychiatry 2022; 75: 38–45.
    1. Buttery S, Philip KEJ, Williams P et al. Patient symptoms and experience following COVID‐19: Results from a UK‐wide survey. 2021.
    1. Ahmed GK, Khedr EM, Hamad DA, Meshref TS, Hashem MM, Aly MM. Long term impact of Covid‐19 infection on sleep and mental health: A cross‐sectional study. Psychiatry Res. 2021; 305: 114243.
    1. Grover S, Sahoo S, Mishra E et al. Fatigue, perceived stigma, self‐reported cognitive deficits and psychological morbidity in patients recovered from COVID‐19 infection. Asian J. Psychiatr. 2021; 64: 102815.
    1. Coping with PTSD from the COVID‐19 Pandemic | Patient Care [Cited 17 October 2022.] Available from URL:
    1. Carmassi C, Foghi C, Dell'Oste V et al. PTSD symptoms in healthcare workers facing the three coronavirus outbreaks: What can we expect after the COVID‐19 pandemic. Psychiatry Res. 2020; 292: 113312.
    1. Ferrando SJ, Dornbush R, Lynch S et al. Neuropsychological, medical, and psychiatric findings after recovery from acute COVID‐19: A cross‐sectional study. J. Acad. Consult. Psychiatry 2022; 63: 474–548.
    1. Dressing A, Bormann T, Blazhenets G et al. Neuropsychological profiles and cerebral glucose metabolism in neurocognitive long COVID‐syndrome. J. Nucl. Med. 2022; 63: 1058–1063.
    1. Aiello EN, Fiabane E, Manera MR et al. Screening for cognitive sequelae of SARS‐CoV‐2 infection: A comparison between the Mini‐Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA). Neurol. Sci. 2022; 43: 81–84 [Cited 20 July 2022.] Available from URL: .
    1. Krishnan K, Miller AK, Reiter K, Bonner‐jackson A. Neurocognitive profiles in patients with persisting cognitive symptoms associated with COVID‐19. 2022; 00: 1–9.
    1. Whiteside DM, Basso MR, Naini SM et al. Outcomes in post‐acute sequelae of COVID‐19 (PASC) at 6 months post‐infection part 1: Cognitive functioning. Clin. Neuropsychol. 2022; 36: 806–828.
    1. Trzepacz PT, Hochstetler H, Wang S, Walker B, Saykin AJ. Relationship between the Montreal Cognitive Assessment and Mini‐mental State Examination for assessment of mild cognitive impairment in older adults. BMC Geriatr. 2015; 15: 107. [Cited 21 July 2022.] Available from URL: .
    1. Giurgi‐oncu C, Tudoran C, Pop GN et al. Cardiovascular abnormalities and mental health difficulties result in a reduced quality of life in the post‐acute COVID‐19 syndrome. Brain Sci. 2021; 2: 1–13.
    1. Ferrucci R, Dini M, Rosci C et al. One‐year cognitive follow‐up of COVID‐19 hospitalized patients. Eur. J. Neurol. 2022; 29: 2006–2014 [Cited 20 July 2022.] Available from URL: .
    1. Shiwaku H, Doi S, Miyajima M et al. Novel brief screening scale, Tokyo Metropolitan Distress Scale for Pandemic (TMDP), for assessing mental and social stress of medical personnel in COVID‐19 pandemic. Psychiatry Clin. Neurosci. 2021; 75: 24–25 [Cited 20 July 2022.] Available from URL: .
    1. Kuroda N, Kubota T, Horinouchi T et al. Risk factors for psychological distress in electroencephalography technicians during the COVID‐19 pandemic: A national‐level cross‐sectional survey in Japan. Epilepsy Behav. 2021; 125: 108361 [Cited 20 July 2022.] Available from URL: .
    1. Ceban F, Ling S, Lui LMW et al. Fatigue and cognitive impairment in post‐COVID‐19 syndrome: A systematic review and meta‐analysis. Brain Behav. Immun. 2022; 101: 93–135.
    1. Glynne P, Tahmasebi N, Gant V, Gupta R. Long COVID following mild SARS‐CoV‐2 infection: Characteristic T cell alterations and response to antihistamines. J. Invest. Med. 2022; 70: 61–67.
    1. Bungenberg J, Humkamp K, Hohenfeld C et al. Long COVID‐19: Objectifying most self‐reported neurological symptoms. 2022; 2.
    1. Maamar M, Artime A, Pariente E et al. Post‐COVID‐19 syndrome, low‐grade inflammation and inflammatory markers: A cross‐sectional study. Curr. Med. Res. Opin. 2022; 38: 901–909.
    1. Molnar T, Varnai R, Schranz D et al. Severe fatigue and memory impairment are associated with lower serum level of Anti‐SARS‐CoV‐2 antibodies in patients with post‐COVID symptoms. J. Clin. Med. 2021; 10: 4337.
    1. Fernández‐Castañeda A, Lu P, Geraghty AC et al. Mild respiratory SARS‐CoV‐2 infection can cause multi‐lineage cellular dysregulation and myelin loss in the brain. bioRxiv 2022. 10.1101/2022.01.07.475453.
    1. Viszlayová D, Sojka M, Dobrodenková S et al. SARS‐CoV‐2 RNA in the cerebrospinal fluid of a patient with long COVID. 2021; 8. 10.1177/20499361211048572.
    1. Schweitzer F, Goereci Y, Franke C et al. Cerebrospinal fluid analysis post‐COVID‐19 is not suggestive of persistent central nervous system infection. Ann. Neurol. 2022; 91: 150–157.
    1. Kubota T, Gajera PK, Kuroda N. Meta‐analysis of EEG findings in patients with COVID‐19. Epilepsy Behav. 2020; 115: 107682.
    1. Ortelli P, Ferrazzoli D, Sebastianelli L et al. Neuropsychological and neurophysiological correlates of fatigue in post‐acute patients with neurological manifestations of COVID‐19: Insights into a challenging symptom. J. Neurol. Sci. 2021; 420: 117271 [Cited 20 July 2022.] Available from URL: .
    1. Tian T, Wu J, Chen T et al. Long‐term follow‐up of dynamic brain changes in patients recovered from COVID‐19 without neurological manifestations: 1–12.
    1. Kiatkittikul P, Promteangtrong C, Kunawudhi A, Siripongsatian D. Abnormality pattern of F‐18 FDG PET whole body with functional MRI brain in post‐acute COVID‐19. Nucl. Med. Mol. Imaging 2022; 56: 29–41.
    1. Benedetti F, Palladini M, Paolini M et al. Brain correlates of depression, post‐traumatic distress, and inflammatory biomarkers in COVID‐19 survivors: A multimodal magnetic resonance imaging study. Brain Behav. Immun. Health 2021; 18: 100387.
    1. Ammar A, Distinguin L, Chetrit A et al. Transient modifications of the olfactory bulb on MR follow‐up of COVID‐19 patients with related olfactory dysfunction. J. Neuroradiol. 2022; 49: 329–332.
    1. Hugon J, Flore E, Mathieu M, Karim Q, Claire F. Long COVID: Cognitive complaints (brain fog) and dysfunction of the cingulate cortex. J. Neurol. 2022; 269: 44–46.
    1. Hugon J, Farid K, Queneau M, Paquet C, Ortiz MS, Msika EF. Cognitive decline and brainstem hypometabolism in long COVID: A case series. 2022. 1–5.
    1. Guedj E, Campion JY, Dudouet P et al. 18F‐FDG brain PET hypometabolism in patients with long COVID. Eur. J. Nucl. Med. Mol. Imaging 2021; 48: 2823–2833.
    1. Verger A, Kas A, Dudouet P, Goehringer F, Salmon‐Ceron D, Guedj E. Visual interpretation of brain hypometabolism related to neurological long COVID: A French multicentric experience. Eur. J. Nucl. Med. Mol. Imaging 2022; 49: 3197–3202 [Cited 20 July 2022.] Available from URL: .
    1. Morand A, Campion JY, Lepine A et al. Similar patterns of [18F]‐FDG brain PET hypometabolism in paediatric and adult patients with long COVID: A paediatric case series. Eur. J. Nucl. Med. Mol. Imaging 2022; 49: 913–920 [Cited 20 July 2022.] Available from URL: .
    1. Sollini M, Morbelli S, Ciccarelli M et al. Long COVID hallmarks on [18F] FDG‐PET/CT: A case–control study. Eur. J. Nucl. Med. Mol. Imaging 2021; 48: 3187–3197 [Cited 20 July 2022.] Available from URL: .
    1. Blazhenets G, Schroeter N, Bormann T et al. Slow but evident recovery from neocortical dysfunction and cognitive impairment in a series of chronic COVID‐19 patients. J. Nucl. Med. 2021; 62: 910–915 [Cited 20 July 2022.] Available from URL: .
    1. Fontana IC, Souza DG, Pellerin L, Souza DO, Zimmer ER. About the source and consequences of 18F‐FDG brain PET hypometabolism in short and long COVID‐19. Eur. J. Nucl. Med. Mol. Imaging 2021; 48: 2674–2675 [Cited 20 July 2022.] Available from URL: .
    1. Meyer PT, Hellwig S, Blazhenets G, Hosp JA. Molecular imaging findings on acute and long‐term effects of COVID‐19 on the brain: A systematic review. 2022.
    1. Stefanou M, Palaiodimou L, Bakola E et al. Neurological manifestations of long‐COVID syndrome: A narrative review. 2022. 1–21.
    1. Wu Y, Xu X, Chen Z et al. Nervous system involvement after infection with COVID‐19 and other coronaviruses. Brain. Behav. Immun. 2020; 87: 18–22.
    1. Lippi A, Domingues R, Setz C, Outeiro TF, Krisko A. SARS‐CoV‐2: At the crossroad between aging and neurodegeneration. Mov. Disord. 2020; 35: 716–720 [Cited 24 July 2022.] Available from URL: .
    1. Thye AYK, Law JWF, Tan LTH et al. Psychological symptoms in COVID‐19 patients: Insights into pathophysiology and risk factors of long COVID‐19. Biology (Basel) 2022; 11: 61 [Cited 20 July 2022.] Available from URL: .
    1. Manzano GS, McEntire CRS, Martinez‐Lage M, Mateen FJ, Hutto SK. Acute disseminated encephalomyelitis and acute hemorrhagic leukoencephalitis following COVID‐19: Systematic review and meta‐synthesis. Neurol. Neuroimmunol. Neuroinflammation 2021; 8: e1080.
    1. Matteo E, Romoli M, Calabrò C et al. Combined central and peripheral demyelination with anti‐neurofascin155 IgG following COVID‐19 vaccination. Can. J. Neurol. Sci. 2021; 13: 1–3 [Cited 29 June 2022.] Available from URL: .
    1. Kappelmann N, Dantzer R, Khandaker GM. Interleukin‐6 as potential mediator of long‐term neuropsychiatric symptoms of COVID‐19. Psychoneuroendocrinology 2021; 131: 105295 [Cited 24 July 2022.] Available from URL: .
    1. Matschke J, Lütgehetmann M, Hagel C et al. Neuropathology of patients with COVID‐19 in Germany: A post‐mortem case series. Lancet Neurol. 2020; 19: 919–929 [Cited 24 July 2022.] Available from URL: .
    1. Wang C, Zhang M, Garcia G et al. ApoE‐isoform‐dependent SARS‐CoV‐2 neurotropism and cellular response. Cell Stem Cell 2021; 28: 331–342.e5 [Cited 24 July 2022.] Available from URL: .
    1. Sun B, Tang N, Peluso MJ et al. Characterization and biomarker analyses of post‐COVID‐19 complications and neurological manifestations. Cell 2021; 10: 1–18 [Cited 24 July 2022.] Available from URL: .
    1. Kell DB, Laubscher GJ, Pretorius E. A central role for amyloid fibrin microclots in long COVID/PASC: Origins and therapeutic implications. Biochem. J. 2022; 479: 537–559.
    1. The microvascular hypothesis underlying neurologic manifestations of long COVID‐19 and possible therapeutic strategies. Cardiovasc. Endocrinol. Metab. 2021; 10: 193–203 [Cited 20 July 2022.] Available from URL: .
    1. Montagne A, Nation DA, Sagare AP et al. APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline. Nature 2020; 581: 71–76.
    1. Kurki SN, Kantonen J, Kaivola K et al. APOE ε4 associates with increased risk of severe COVID‐19, cerebral microhaemorrhages and post‐COVID mental fatigue: A Finnish biobank, autopsy and clinical study. Acta Neuropathol. Commun. 2021; 9: 1–13.
    1. Valente KD, Alessi R, Baroni G, Marin R, dos Santos B, Palmini A. The COVID‐19 outbreak and PNES: The impact of a ubiquitously felt stressor. Epilepsy Behav. 2021; 117: 107852. [Cited 21 July 2022.] Available from URL: .
    1. Vindegaard N, Benros ME. COVID‐19 pandemic and mental health consequences: Systematic review of the current evidence. Brain Behav. Immun. 2020; 89: 531–542 [Cited 21 July 2022.] Available from URL: .
    1. Maglietta G, Diodati F, Puntoni M et al. Prognostic factors for post‐COVID‐19 syndrome: A systematic review and meta‐analysis. J. Clin. Med. 2022; 11: 1541. [Cited 24 July 2022.] Available from URL: .
    1. Huang L, Yao Q, Gu X et al. 1‐year outcomes in hospital survivors with COVID‐19: A longitudinal cohort study. Lancet 2021; 398: 747–758 [Cited 21 July 2022.] Available from URL: .
    1. Righi E, Mirandola M, Mazzaferri F et al. Determinants of persistence of symptoms and impact on physical and mental wellbeing in long COVID: A prospective cohort study. J. Infect. 2022; 84: 566–572 [Cited 24 July 2022.] Available from URL: .
    1. Sadat F, Atiye M, Jamab S, Pereira V, Kordi A. Chronic fatigue syndrome and cognitive deficit are associated with acute‐phase neuropsychiatric manifestations of COVID‐19: A 9‐month follow‐up study. Neurol. Sci. 2022; 43: 2231–2239.
    1. Munblit D, Bobkova P, Spiridonova E et al. Incidence and risk factors for persistent symptoms in adults previously hospitalized for COVID‐19. Clin. Exp. Allergy 2021; 51: 1107–1120 [Cited 24 July 2022.] Available from URL: .
    1. Fernández‐de‐las‐Peñas C, Gómez‐Mayordomo V, García‐Azorín D et al. Previous history of migraine is associated with fatigue, but not headache, as long‐term post‐COVID symptom after severe acute respiratory SARS‐CoV‐2 infection: A case–control study. Front. Hum. Neurosci. 2021; 15 [Cited 24 July 2022.] Available from URL: .
    1. Fernández‐de‐las‐Peñas C, Gómez‐Mayordomo V, Cuadrado ML et al. The presence of headache at onset in SARS‐CoV‐2 infection is associated with long‐term post‐COVID headache and fatigue: A case–control study. Cephalalgia 2021; 41: 1332–1341 [Cited 24 July 2022.] Available from URL: .
    1. Islam MK, Molla MMA, Hasan P et al. Persistence of sleep disturbance among post‐COVID patients: Findings from a 2‐month follow‐up study in a Bangladeshi cohort. J. Med. Virol. 2022; 94: 971–978 [Cited 24 July 2022.] Available from URL: .
    1. Fernández‐de‐las‐Peñas C, Torres‐Macho J, Elvira‐Martínez CM, Molina‐Trigueros LJ, Sebastián‐Viana T, Hernández‐Barrera V. Obesity is associated with a greater number of long‐term post‐COVID symptoms and poor sleep quality: A multicentre case–control study. Int. J. Clin. Pract. 2021; 75: e14917 [Cited 24 July 2022.] Available from URL: .
    1. Fernández‐de‐las‐Peñas C, Torres‐Macho J, Velasco‐Arribas M et al. Preexisting hypertension is associated with a greater number of long‐term post‐COVID symptoms and poor sleep quality: A case–control study. J. Hum. Hypertens. 2022; 36: 582–584 [Cited 24 July 2022.] Available from URL: .
    1. Gouraud C, Bottemanne H, Lahlou‐Laforêt K et al. Association between psychological distress, cognitive complaints, and neuropsychological status after a severe COVID‐19 episode: A cross‐sectional study. Front. Psychiatry 2021; 12: 1–7.
    1. Valdes E, Fuchs B, Morrison C et al. Demographic and social determinants of cognitive dysfunction following hospitalization for COVID‐19. J. Neurol. Sci. 2022; 438 [Cited 28 June 2022.] Available from URL: .
    1. Cristillo V, Pilotto A, Cotti Piccinelli S et al. Premorbid vulnerability and disease severity impact on long‐COVID cognitive impairment. Aging Clin. Exp. Res. 2022; 34: 257–260.
    1. Delgado‐Alonso C, Valles‐Salgado M, Delgado‐álvarez A et al. Examining association of personality characteristics and neuropsychiatric symptoms in post‐COVID syndrome. Brain Sci. 2022; 12: 265.
    1. Azevedo MN, Rodrigues E d S, Passos EAFV et al. Multimorbidity associated with anxiety symptomatology in post‐COVID patients. Psychiatry Res. 2022; 309: 309–312.
    1. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6‐month neurological and psychiatric outcomes in 236 379 survivors of COVID‐19: A retrospective cohort study using electronic health records. Lancet Psychiatry 2021; 8: 416–427.
    1. Garcı M, Sankowski R. Neurocognitive and psychiatric post‐coronavirus disease 2019 conditions: Pathogenic insights of brain dysfunction following severe acute respiratory syndrome coronavirus 2 infection. 2022.
    1. Fernández‐De‐Las‐Peñas C, Martín‐Guerrero JD, Cancela‐Cilleruelo I, Moro‐López‐Menchero P, Rodríguez‐Jiménez J, Pellicer‐Valero OJ. Trajectory curves of post‐COVID anxiety/depressive symptoms and sleep quality in previously hospitalized COVID‐19 survivors: The long‐COVID‐EXP‐CM multicenter study. Psychol. Med. 2022: 1–2 [Cited 20 July 2022.] Available from URL: .
    1. Schou TM, Joca S, Wegener G, Bay‐Richter C. Psychiatric and neuropsychiatric sequelae of COVID‐19 – A systematic review. Brain Behav. Immun. 2021; 97: 328–348 [Cited 20 July 2022.] Available from URL: .
    1. Garcia‐Azorin D, Layos‐Romero A, Porta‐Etessam J et al. Post‐COVID‐19 persistent headache: A multicentric 9‐months follow‐up study of 905 patients. Cephalalgia 2022; 42: 804–809 [Cited 20 July 2022.] Available from URL: .
    1. Borch L, Holm M, Knudsen M, Ellermann S, Soeren E. Long COVID symptoms and duration in SARS‐CoV‐2 positive children – A nationwide cohort study. Eur. J. Pediatr. 2022; 181: 1597–1607.
    1. Fortunato F, Martinelli D, Iannelli G et al. Self‐reported olfactory and gustatory dysfunctions in COVID‐19 patients: A 1‐year follow‐up study in Foggia district, Italy. BMC Infect. Dis. 2022; 22: 77 [Cited 20 July 2022.] Available from URL: .
    1. Rass V, Beer R, Schiefecker AJ et al. Neurological outcomes 1 year after COVID‐19 diagnosis: A prospective longitudinal cohort study. Eur. J. Neurol. 2022; 29: 1685–1696 [Cited 20 July 2022.] Available from URL: .
    1. Daynes E, Gerlis C, Chaplin E, Gardiner N, Singh SJ. Early experiences of rehabilitation for individuals post‐COVID to improve fatigue, breathlessness exercise capacity and cognition – A cohort study. Chron. Respir. Dis. 2021; 18: 14799731211015691.
    1. Priyamvada R, Ranjan R, Chaudhury S. Efficacy of psychological intervention in patients with post‐COVID‐19 anxiety. 2021; 30.
    1. Krymchantowski AV, Pereira R, Néto S, Jevoux C, Gabriela A. Indomethacin for refractory COVID or post‐COVID headache: A retrospective study. Acta Neurol. Belg. 2022; 122: 465–469.
    1. Webster KE, O'Byrne L, MacKeith S, Philpott C, Hopkins C, Burton MJ. Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction. Cochrane Database Syst. Rev. 2022; 9: CD013877 [Cited 20 July 2022.] Available from URL: .
    1. Wu TJ, Yu AC, Lee JT. Management of post‐COVID‐19 olfactory dysfunction. Curr. Treat. Options Allergy 2022; 9: 1–18.
    1. Bogucki OE, Sawchuk CN. Cognitive processing therapy for posttraumatic stress disorder due to COVID‐19‐related traumas: A case study. Psychol. Serv. 2022. 10.1037/ser0000630
    1. Taquet M, Harrison PJ. Exposure to phenytoin associates with a lower risk of post‐COVID cognitive deficits: A cohort study. Brain Commun. 2022; 4: 1–8.
    1. Ahmadi Hekmatikar AH, Ferreira Júnior JB, Shahrbanian S, Suzuki K. Functional and psychological changes after exercise training in post‐COVID‐19 patients discharged from the hospital: A PRISMA‐compliant systematic review. Int. J. Environ. Res. Public Health 2022; 19: 2290.
    1. Abdelalim AA, Mohamady AA, Elsayed RA, Elawady MA, Ghallab AF. Corticosteroid nasal spray for recovery of smell sensation in COVID‐19 patients: A randomized controlled trial. Am. J. Otolaryngol. 2021; 42: 102884 [Cited 20 July 2022.] Available from URL: .
    1. Karosanidze I, Kiladze U, Kirtadze N et al. Efficacy of adaptogens in patients with long COVID‐19: A randomized, quadruple‐blind, placebo‐controlled trial. Pharmaceuticals (Basel) 2022; 15: 345 [Cited 20 July 2022.] Available from URL: .
    1. Jarrott B, Head R, Pringle KG, Lumbers ER, Martin JH. “LONG COVID” – A hypothesis for understanding the biological basis and pharmacological treatment strategy. Pharmacol. Res. Perspect. 2022; 10: 1–10.
    1. Guo ZP, Sörös P, Zhang ZQ, Yang MH, Liao D, Liu CH. Use of transcutaneous auricular vagus nerve stimulation as an adjuvant therapy for the depressive symptoms of COVID‐19: A literature review. Front. Psychiatry 2021; 12: 2239.
    1. Azzolini E, Levi R, Sarti R et al. Association between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in health care workers. JAMA 2022; [Cited 26 July 2022.] Available from URL: ; 328: 676–678.
    1. Al‐Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS‐CoV‐2 infection. Nat. Med. 2022; 28: 1461–1467 [Cited 26 July 2022.] Available from URL: .

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel